Chronic obstructive pulmonary disease: Role of matrix metalloproteases and future challenges of drug therapy

Expert Opinion on Investigational Drugs

Volumn 16, Issue 7, 2007, Pages 1069-1078

  Srivastava, Punit K ^a   Dastidar, Sunanda G ^a   Ray, Abhijit ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Cigarette smoke; COPD; Emphysema; Fibrosis; Inflammation; Matrix metalloprotease

Indexed keywords

BAMBUTEROL; BATIMASTAT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CYTOKINE RECEPTOR ANTAGONIST; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; GELATINASE B INHIBITOR; GLUCOCORTICOID; ILOMASTAT; INTERSTITIAL COLLAGENASE; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MACROPHAGE ELASTASE INHIBITOR; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; RESVERATROL; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRONCHODILATATION; CARDIOVASCULAR DISEASE; CD8+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; EMPHYSEMA; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HEALTH CARE COST; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPOKALEMIA; INFLAMMATORY CELL; LOW DRUG DOSE; MACROPHAGE; NAUSEA AND VOMITING; NEUTROPHIL; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUGS, INVESTIGATIONAL; FEMALE; FORECASTING; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34447529140     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.7.1069     Document Type: Review

References (72)

1. MATSUMOTO H, NIIMI A, TAKEMURA M et al.: Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibition in asthma. Thorax (2005) 60:277-281.
2. HOGG JC, CHU F, UTOKAPRACH S et al.: The nature of small-airway obstruction in chronic obstructive lung disease. N. Engl. J. Med. (2004) 350:2645-2654.
3. CELLI BR, MACNEE W: Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease: a summary of the ATS/ERS position paper. Eur. Respir. J. (2004) 23:613-620.
4. PAUWELS RA, ROBE KI: Burden and clinical features of chronic obstructive pulmonary disease. Lancet (2004) 364:613-620.
5. FATMANN CI, CHANG LY, TERMIN TA et al.: Enhanced bleomycin induced pulmonary damage in mice lacking extra cellular superoxide dismutase. Br. J. Pharmacol. (2000) 131:169-172.
6. DAHESIA M: Therapeutic inhibition of matrix metalloproteinase for the treatment of chronic obstructive pulmonary disease (COPD). Curr. Med. Res. Opini. (2005) 21:557-593.
7. COSIO M, GHEZZO H, HOGG JC et al.: The relations between structural changes in small airway and pulmonary function tests. N. Engl. J. Med. (1978) 298:1277-1281.
8. PENMAN RW: The progress of chronic airway obstruction in relationship of asthma. Am. Rev. Respir. Dis. (1970) 101:536-544.
9. COLEBATCH HJ, FINUCARE KE, SMITH MM et al.: Pulmonary conductance and elastic recoil relationship in asthma and emphysema. J. Appl. Pbysiol. (1973) 34:143-153.
10. HOGG IC: Pathophysiology and airflow limitation in COPD. Lancet (2004) 364:709-721.
11. DI STEFANO A, CAPELLI A, FATTORETTI P et al.: Decreased T-lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy (2001) 31:893-902.
12. DE BOER WI: Cytokines therapy in chronic obstructive pulmonary disease: a promising combination. Chest (2002) 121:2095-2185.
13. BARNES PJ, SHAPIRO SD, PAUWELS RA: Chronic obstructive pulmonary disease: molecular and cellular mechanism. Eur. Respir. J. (2003) 22:672-688.
14. GAULDIE J, KOLB M, SIME PJ: A new direction in the pathogenesis of idiopathic pulmonary fibrosis. Respir. Res. (2002) 3:1-12.
15. STRIEKER RM: Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am. Respir. J. Crit. Care Med. (2002) 16:1206-1207.
16. SHAPIRO SD: COPD unwound. N. Engl. J. Med. (2005) 352:2016-2019.
17. LAGNTE V, MANOURY B, NENAN S et al.: Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz. J. Med. Biol. Res. (2005) 38:1521-1550.
18. SHAPIRO SD: Proteolysis in the lung. Eur. Respir. J. Suppl. (2003) 44:s30-s32.
19. BODE W, GOMIS-RUTH FX, STÖCKER W et al.: Astacins, serralysins, snake venom and MMP exhibit identical zinc binding environments (HEXXHXXGXXH & Met-turn) and topologist end should be grouped into common family, the metazincins. FEBS Lett. (2002) 331:134-140.
20. GOMIS-RUTH FX: Structural aspects of the metzincin class of metallopeptidase. Mol. Biotechnol. (2003) 24:157-202.
21. SATO H, TAKINO T, OKADA Y et al.: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature (1994) 370:61-65.
22. LOVEJOY B, CLEASTRY A, HASSEL AM et al.: Structure of the catalytic domain of fibroblast collagenase. Science (1994) 263:375-377.
23. STOCKET W, BODE W: Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. Opin. Struct. Biol. (1995) 5:383-390.
24. NAGASE H, VISSE R, MURPHY G: Structure and function of matrix metalloproteinase and TIMPs. Cardiovas. Res. (2006) 69:562-573.
25. BABINE RE, BENDER SL: Molecular recognition of protein ligand complexes: application of drug design. Chem. Rev. (1997) 97:1359-1472.
26. WHITTAKER M, PLOYD CD, BROWN P et al.: Design and therapeutic application of MMP inhibitors. Chem. Rev. (1999) 99:2735-2776.
27. MARCHENKO MD, MARCHENKO GN, WEINBERG RN et al.: β-catenin regulates the gene of MMP-26, a novel metalloprotease expressed both in cancerous and normal epithelial cells. Int. J. Biochem. Cell Biol. (2004) 36:942-956.
28. MARTORMA PA, VAS EVEN P, GARDI C et al.: A 16 month study of the development of the genetic emphysema in the tight skin mice. Am. Rev. Respir. Dis. (1989) 139:226-232.
29. RANGA V, GRAHN D, JOURNEY TM: Macrophage and phenotypic analysis of outcross line of blotchy mouse. Am. Rev. Respir. Dis. (1983) 139:226-232.
30. WANDEL DP, TAYLOR DG, ALBERTINE KH et al.: Impaired distal airway development in mice lacking elastin. Respir. Cell Mol. Biol. (2000) 23:320-326.
31. HAUTAMAKI RD, KOBAYASHI DK, SENIOR RM et al.: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277:2002-2004.
32. HOLEBECK K, BIANCO P, CATERINA J et al.: MT-1-MMP deficient mice develop dwarfism; osteropenia, arthritis and connective tissue disease due to inadequate collagen turn over. Cell (1999) 99:81-92.
33. SNIDER GL: Emphysema: the first centuries and beyond: a historical overview with suggestions for future research: part 2. Am. Rev. Respir. Dis. (1992) 146:1615-1622.
34. MASSARO GD, MASSARO D: Retinoic add treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. 3:675-677.
35. KUHN C, STARCHER BC: The effect of lathyrogens on the evolution of elastase-induced emphysema. Am. Rev. Respir. Dis. (1980) 122:453-460.
36. DE BOER WI: Perspectives for cytokine antagonist therapy in COPD. Drug Discov. Today (2005) 10:93-106.
37. RUSSELL RE, THORLEY A, CULPITT SV et al.: Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinase, cysteine and serine proteases. Am. J. Physiol. (2002) 283:L867-L873.
38. SUTHERLAND ER, CHERNIASK RM: Management of chronic obstructive pulmonary disease N. Engl. J. Med. (2004) 350:2689-2697.
39. OSHITA Y, KOGA T, KAMIMURA T et al.: Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma. Thorax (2003) 58:757-760.
40. MERCER PF, SHUTE JK, BHOWMIK A et al.: MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients drug exacerbation. Respir. Res. (2005) 22:151-159.
41. PETERSON JT: Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail. Rev. (2004) 91:63-79.
42. BIRRELL MA, SISSIE W, DEKKAK A et al.: Role of Matrix metalloproteases in the inflammatory response in human airway cell based assays and in rodent models of airway diseases. J. Pharmacol. Exp. Therap. (2006) 318:741-750.
43. LECLERC O, LAGENTE V, PLANQUOIS JM et al.: Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur. Respir. J. (2006) 27:1102-1109.
44. NOE V, FINGETON B, JACOBS K et al.: Release of an invasion promoter E-cadherin fragment by Matrilysin and Stromolysin-1. J. Cell Sci. (2001) 114:111-118.
45. STEINHUSEN U, WEIKE J, BADOK V et al.: Cleave and shedding of E-cadherin after induction of apoptosis. J. Biol. Chem. (2001) 276:4972-4980.
46. NING WN, YINYING D, SUN J et al.: Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. (2007) 36:480-490.
47. MANNINO DM, GAGNON RC, PETTY TL, LYDICK E: Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey. Arch. Intern. Med. (2000) 160:1683-1689.
48. MANNINO DM, HOMA DM, AKINBAMI LJ, FORD ES, REDD SC: Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill. Summ. (2002) 51:1-16.
49. FLETCHER C, PETO R, TINKER C et al.: The natural history of chronic bronchitis and emphysema. New York. Oxford University Press (1976).
50. O'DONNELL DE, LAM M, WEBB KA: Spirometric correlates of improvement in exercise performance after anti-cholinergic therapy in chronic obstructive pulmonary disease. Am J. Respir. Crit. Care Med. (1999) 160:542-549.
51. RENNARD SI, SERBY CW, GHAFOURI M et al.: Extended therapy with ipatropium is associated with improved lung function in COPD: a retrospective analysis of data from seven clinical trials. Chest (1996) 110:62-70.
52. JARVIS B, MARKHAM A: Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging (2001) 18:441-472.
53. HANSEL TT, BARNES PJ: Tiotropium bromide: a novel once-daily anti-cholinergic bronchodilator for the treatment of COPD. Drugs Today (2002) 38:585-600.
54. BARNESS PJ: Theophylline: new perspective for an old drug. Am. J. Respir. Crit. Care Med. (2002) 165:1371-1376.
55. VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (1999) 353:1819-1823.
56. BURGE PS, CALVERLEY PM, JONES PW et al.: Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trail. BMJ (2000) 320:1297-1303.
57. CALVERLEY P, PAUWELS R, VESTBO J et al.: combined salmesterol and flucticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (2003) 361:449-456.
58. BARNES PJ, HANSEL TT: Prospects for new drugs for chronic obstructive pulmonary disease. Lancet (2004) 364:985-996.
59. MACNEE W: Oxidants/antioxidants and COPD. Chest (2000) 117:S303-S317.
60. CULPITT SV, ROGERS DF, FENWICK PS et al.: Inhibition by red wine extract, resvertrol, of cytokine release by alveolar macrophages in COPD. Thorax (2003) 58:942-946.
61. MONTUSCHI P, KHARITONOV SA, CIABATTONI G et al.: Exhaled leukotrienes and prostaglandins in COPD. Thorax (2003) 58:585-988.
62. COMPTON CH, GUBB J, NEIMAN R et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized, dose-ranging study. Lancet (2001) 358:265-270.
63. 2-adrenoreceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. (2002) 110:1045-1052.
64. CHURG R, WANG R, WNG X et al.: An MMP-9/-12 inhibitor prevents smoke-induced emphysema and small airway remodeling in guinea pigs. Thorax (2007) 20: (In Press).
65. COUSSENS LM: Matrix metalloproteinase inhibitors and cancers: trials and tribulations. Science (2002) 295:2387-2392.
66. CUNIASSE P, DEVEL L, MAKARITIS A et al.: Future challenges facing the development of specific active-site directed synthetic inhibitors of MMPs. Biochimie (2005) 87:393-402.
67. LOPEZ-OTIN C, OVERALL CM: Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. (2002) 3:509-519.
68. BERGERS G, BREKLEN R, MCMOHAN M et al.: MMP-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. (2000) 2:734-744.
69. ROSEMURGY A, HARRIS J, LANGLEBEN A et al.: Marimastat in patients with advanced pancreatic cancer: a dose finding study. Clin. Oncol. (1999) 99:2735-3776.
70. BROWN PD: Ongoing trials with MMP inhibitors. Expert Opin. Investig. Drugs (2000) 9:2167-2177.
71. WILSON S, WAKELAM MJO, HOBBS RFD et al.: Evaluation of the accuracy of serum MMP-9 as a test of colorectal cancer in a primary care population. Bio. Med. Central Cancer (2006) 6:258-264.
72. MOLFINO NA: Current thinking on genetics of chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. (2006) 13:107-113.